Gilead Trodelvy First-Line TNBC Approval

Summary The FDA approved Trodelvy for first-line metastatic triple-negative breast cancer, significantly expanding Gilead’s commercial opportunity and reinforcing TROP2-directed ADCs as a leading oncology modality. What Happened The approval moves Trodelvy into frontline metastatic TNBC, where it will compete directly with emerging TROP2 ADCs including…